Jinwon Life Sciences Publishes Research on Suction-Based Intradermal Injection Platform in International Science Journal

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 8th that the research results on the platform development of the DNA vaccine suction-based intradermal injection device ‘GeneDerm’ were published in ‘Science Advances,’ a sister journal of Science, which is internationally renowned and highly cited.

GeneOne Life Science explained, “The title of the paper is ‘Novel suction-based in vivo cutaneous DNA transfection platform.’ The platform development was conducted jointly with the engineering research team at Rutgers University, USA, and it is currently applied to the COVID-19 DNA vaccine (GLS-5310), which is undergoing Phase 1/2a clinical trials.”

According to the paper, “This technology, which does not cause damage to the administration site during vaccination, not only excellently induces intracellular delivery of the DNA vaccine and antigen expression but also elicited a high level of immune response to GLS-5310.”

A GeneOne Life Science official stated, “The hamster challenge infection study using GLS-5310 with this injection platform completely prevented lung infection not only from the wild-type COVID-19 virus but also from the Beta variant. Additionally, antibodies formed after vaccination were confirmed by the ACE2-RBD binding assay to inhibit not only the wild-type but also the Delta variant. Furthermore, the first interim results of the Phase 1 clinical immunogenicity evaluation of GLS-5310, which has already been announced, showed that vaccination using the GeneDerm platform induced strong and high antibody immune responses and T-cell immune responses.”

Park Young-geun, CEO of GeneOne Life Science, said, “The research results published in the top scientific journal are the outcome of years of efforts to develop a DNA vaccine administration method that is inexpensive, capable of mass production, and easy to use to facilitate the supply of DNA vaccines. Together with the brilliant efforts of the Rutgers University engineering research team, we have studied intracellular delivery of DNA and developed a very effective administration method for DNA vaccines and DNA-based therapeutics, marking a milestone in the development process of DNA vaccines and therapeutics.”

He added, “Since GeneDerm induces gene expression within just one hour after administration, it is judged to have excellent potential not only in the field of vaccines for emerging infectious diseases but also in DNA-based therapeutics for cancer treatment, where immediate therapeutic effects are required.”

This content was produced with the assistance of AI translation services.